Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "survivin" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-6 z 6
    Tytuł:
    Reversal of drug resistance by silencing Survivin gene expression in acute myeloid leukemia cells
    Autorzy:
    Wu, Yao-Hui
    You, Yong
    Chen, Zhi-Chao
    Zou, Ping
    Powiązania:
    https://bibliotekanauki.pl/articles/1040668.pdf
    Data publikacji:
    2008
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    chemotherapeutic resistance
    Survivin
    acute myeloid leukemia
    shRNA
    apoptosis
    Opis:
    The role of Survivin in the pathogenesis of leukemia was explored in order to discover the effective avenues for gene therapy. Most primary leukemia cells isolated from patients as well as three leukemia cell lines (HL-60, K562, and U937) all expressed Survivin gene. To investigate the relationship between Survivin and chemotherapeutic resistance, HL-60 cells were treated with daunorubicin (DNR), mitoxantrone (MIT) or arsenious oxide (As2O3), and it was found that after 24 h the level of Survivin mRNA was decreased by 9.7%, 41.0% and 27.5%, respectively. At 72 h, the level of Survivin mRNA was increased by 21.2% and 65.2% in HL-60 cells treated with DNR or MIT, but decreased by 33.2% in those treated with As2O3 as compared with that in the cells treated for 24 h. These results showed that DNR and MIT could initally decrease the expression of Survivin and then increase it, but As2O3 could decrease the Survivin expression continually. Furthermore, shRNA plasmids targeting the Survivin gene (pEGFP-Survivin), which can silence the expression of Survivin with a high specificity, were constructed. pEGFP-Survivin and pEGFP-H1 were transfected into HL-60 cells via electroporation and selected by G418, and HL-60/Survivin and HL-60/EGFP cells were obtained. After treatment with DNR, the cell survival rate and IC50 of DNR in HL-60/Survivin cells were decreased substantially as compared with those of HL-60/EGFP and HL-60 cells (IC50 of DNR: 18.3 ± 2.45 vs 40.8 ± 6.37 and 39.2 ± 5.91 ng/ml, respectively), and the apoptosis rate was elevated ((84.3 ± 19.7)% vs (45.8 ± 13.8)% and (50.9 ± 12.4)%, respectively). These results suggest that shRNA can down-regulate the expression of Survivin in HL-60 cells substantially and improve their sensitivity to DNR. They also further explain the pathogenesis of leukemia drug resistance and provide new theory in the design of clinical therapies.
    Źródło:
    Acta Biochimica Polonica; 2008, 55, 4; 673-680
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Vascular Endothelial Growth Factor and Survivin Immunostaining in Gastric Adenocarcinoma
    Autorzy:
    Bury, Jarosław
    Szumiło, Justyna
    Dąbrowski, Andrzej
    Ciechański, Aleksander
    Śliwińska, Justyna
    Wallner, Grzegorz
    Powiązania:
    https://bibliotekanauki.pl/articles/1396680.pdf
    Data publikacji:
    2012-07-01
    Wydawca:
    Index Copernicus International
    Tematy:
    vascular endothelial growth factor
    VEGF
    survivin
    adenocarcinoma
    stomach
    survival
    Opis:
    Two molecules - vascular endothelial growth factor involved in new vessels formation and survivin - antiapoptotic protein, reported to be associated with worse prognosis in various malignancies have been chosen for the study. Both are potential target for novel therapiesThe aim of the study was to determine the immunostaining of VEGF and survivin in gastric carcinoma and to analyse their relationship to the selected clinicopathological features and survival.Material and methods. Formalin-fixed, paraffin-embedded sections from 41 gastric adenocarcinomas were used for immunohistochemical reaction with monoclonal antibodies against vascular endothelial growth factor and survivin. The results were compared with selected clinicopathological features and survival.Results. Positive immunohistochemical reaction for vascular endothelial growth factor and survivin was revealed in 24 (58,53%) and 30 (73,17%), gastric carcinomas respectively. Vascular endothelial growth factor-negative gastric carcinomas were significantly more common in cases without metastases to regional lymph nodes and distant organs and in less advanced cases. Similar, distant metastases were also statistically less common in survivin-negative carcinomas. The differences in immunohistochemical reactions for survivin between less and more advanced cases almost reach statistical significance. The only factors significantly influenced 1, 2 and 3-year survival were vascular endothelial growth factor and survivin status. Statistically significant higher percentage of survival was noted in patients with vascular endothelial growth factor- and survivin-negative tumors.Conclusions. It seems that vascular endothelial growth factor and survivin play role in local invasion and spread of gastric adenocarcinoma and negatively influences survival. However, further studies are required to assess their true usefulness in the clinical practice.
    Źródło:
    Polish Journal of Surgery; 2012, 84, 7; 341-347
    0032-373X
    2299-2847
    Pojawia się w:
    Polish Journal of Surgery
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Wybrane czynniki molekularne związane z przerzutowaniem raka jajnika
    Selected molecular factors associated with metastases of ovarian cancer
    Autorzy:
    Markowska, Anna
    Lubin, Jolanta
    Jaszczyńska-Nowinka, Karolina
    Markowska, Janina
    Powiązania:
    https://bibliotekanauki.pl/articles/1031182.pdf
    Data publikacji:
    2012
    Wydawca:
    Medical Communications
    Tematy:
    AEG-1 gene
    E-cadherin
    HER2 gene
    Met gene
    SDF-1 gene
    claudins 3 and 4
    clusterin
    gen AEG-1
    gen HER2
    gen Met
    gen SDF-1
    kadheryna-E
    kalikreiny
    kallikreins
    kisspeptin
    kisspeptyna
    klaudyny 3 i 4
    klusteryna
    metastases
    ovarian cancer
    przerzuty nowotworowe
    rak jajnika
    survivin
    surwiwina
    uPAR
    Opis:
    Development of metastases is a typical feature of cancer progression and the main cause of treatment failure in cancer treatment. Due to their ability to settle far from original tumor location, cancer cells may preserve the feature of immortal cells, enabling survival of tumor and transition to chronic phase of the disease. Applying currently available techniques of topical treatment, such as surgery and radiotherapy, we are unable to control fully spread of cancer cells, while systemic chemotherapy even in chemosensitive tumors does not eradicate the disease in all cases. Ovarian cancer may spread by dissemination within the abdominal cavity and lymphatic vessels, resulting in distant metastases. The process of metastases’ development is extremely complex, depending on many different factors governing intercellular adhesion and acquisition of ability to move and migrate by cancer cells. Tumors with coexisting distant metastases are considered most advanced, which means also a grim prognosis for the patient. Mechanism of metastases’ development is the subject of several studies, attempting to identify factors which might lendthemselves for targeted therapy of cancers, including ovarian cancer. The paper presents genes, their products and other metastases-associated proteins: HER2 gene, AEG-1 gene, kisspeptin, E-cadherin, survivin, uPAR, clusterin, Met gene, claudins 3 and 4, kallikreins, SDF-1 gene. This paper is meant to systematize extensive knowledge on the development of metastases development and synthetic analysis of data concerning this process.
    Przerzutowanie jest cechą charakterystyczną progresji nowotworów złośliwych i główną przyczyną niepowodzeń w leczeniu raka. Dzięki zdolności do występowania w miejscach poza ogniskiem pierwotnym komórki nowotworowe mogą zachować cechę komórek nieśmiertelnych, co pozwala na przetrwanie nowotworu i nazwanie go chorobą przewlekłą. Stosując dostępne dziś metody leczenia miejscowego, takie jak chirurgia i radioterapia, nie jesteśmy w stanie w pełni kontrolować rozprzestrzeniania się komórek nowotworowych, a systemowa chemioterapia w chemiowrażliwych nowotworach nie zawsze „eradykuje” chorobę. Rak jajnika może szerzyć się poprzez rozsiew w jamie brzusznej oraz naczynia chłonne, dając przerzuty odległe. Proces przerzutowania jest niezmiernie złożony, wpływa na niego wiele różnych czynników decydujących o wzajemnym przyleganiu komórek do siebie, nabyciu zdolności ruchliwości i migracji przez komórki nowotworowe. Nowotwory, którym towarzyszą przerzuty odległe, są klasyfikowane jako najbardziej zaawansowane, co oznacza jednocześnie złe rokowanie dla pacjenta. Mechanizm przerzutowania jest przedmiotem wielu badań mających na celu wyłonienie czynników, które mogą być tarczą dla terapii celowanych nowotworów, w tym raka jajnika. W artykule przedstawiono geny i ich produkty oraz inne białka związane z przerzutowaniem: gen HER2, gen AEG-1, kisspeptynę, kadherynę-E, surwiwinę, uPAR, klusterynę, gen Met, klaudyny 3 i 4, kalikreiny, gen SDF-1. Celem pracy było usystematyzowanie obszernej wiedzy na temat przerzutowania oraz syntetyczna analiza danych dotyczących tego procesu.
    Źródło:
    Current Gynecologic Oncology; 2012, 10, 3; 236-243
    2451-0750
    Pojawia się w:
    Current Gynecologic Oncology
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Proinflammatory cytokines (IL-6, IL-18) and apoptotic factors (HP 53, survivin) in patients with alcoholic liver cirrhosis
    Autorzy:
    Prystupa, Andrzej
    Kiciński, Paweł
    Sak, Jarosław
    Grzybowski, Andrzej
    Boguszewska-Czubara, Anna
    Toruń-Jurkowska, Anna
    Niedziałek, Jarosław
    Załuska, Wojciech
    Powiązania:
    https://bibliotekanauki.pl/articles/972717.pdf
    Data publikacji:
    2017
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    survivin
    alcoholic liver cirrhosis
    proinflammatory cytokines
    apoptosis
    human protein p53
    Opis:
    Background. Apoptosis is involved in the pathogenesis of alcoholic liver cirrhosis. Its development can be triggered by an inflammatory process. In the present study, levels of apoptotic factors – survivin human protein p53 (HP 53) and IL-6, IL-18 were determined according to the stage of liver cirrhosis. Material and methods. Seventy patients with alcoholic liver cirrhosis, treated in various hospitals of the Lublin region, Poland were included in the study. Serum levels of IL-6, IL-18, HP53 and survivin were determined by the enzyme-linked immunosorbent assay (ELISA) technique. Results. The serum level of survivin in patients with alcoholic liver cirrhosis was not statistically different from that found in the control group. The level of HP53 was significantly higher in the group of patients with alcoholic liver cirrhosis compared to the control group (16.53±22.69 vs. 0.39±1.31 U/ml; p<0.001). Likewise, the level of IL-6 was significantly higher in the group of patients with alcoholic liver cirrhosis compared to the control group (33.83±41.78 vs. 0.88 ± 0.56 pg/ml; p<0.001). Moreover, the level of IL-18 was significantly higher in the group of patients with liver cirrhosis compared to the control group (23.96±31.07 vs. 5.3±8.6 pg/ml; p<0.001). Conclusion. In conclusion, increased serum levels of IL-6 and IL-18 were demonstrated in patients with alcoholic liver cirrhosis. Moreover, the liver cirrhosis patients had elevated levels of HP53, which is a marker of apoptosis. Our results did not demonstrate the correlation between the levels of apoptosis markers (survivin, HP53) and the levels of cytokines (IL-6, IL-18) in the blood serum.
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2017, 11, 1; 1-5
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Expression of the BIRC5 gene in the presence of adalimumab in normal human dermal fibroblasts (NHDF)
    Autorzy:
    Kaźmierczak, Agata
    Zmarzły, Nikola
    Wcisło-Dziadecka, Dominika
    Powiązania:
    https://bibliotekanauki.pl/articles/1178228.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    NHDF
    adalimumab
    survivin
    Opis:
    Survivin encoded by BIRC5 belongs to the group of proteins that inhibit apoptosis. It consists of the BIR and α-helical C domains. In addition to its inhibitory activity, it plays an important role in cell cycle regulation. Adalimumab is an immunosuppressive drug, a recombinant human anti-TNF-α monoclonal antibody. It is used in the treatment of autoimmune diseases.The aim of the study was to evaluate changes in the expression of BIRC5 and genes encoding apoptosis inhibitors (IAP), depending on the exposure time of the cells to adalimumab. The study material consisted of normal human dermal fibroblasts (NHDF) cultured under standard conditions in the presence of adalimumab (8µg/mL) for 2, 8 and 24 hours. The expression profile of genes associated with apoptosis was determined with the use of HG-U133A 2.0 oligonucleotide microarrays (Affymetrix). The comparative analysis was performed with one-way ANOVA and Tukey's HSD tests (p
    Źródło:
    World Scientific News; 2018, 93; 60-67
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The oncoprotein HBXIP – its functions and roles in oncogenesis
    Autorzy:
    Grudzinska, M.
    Lomperta, K.
    Jakubowska, K.
    Samocik, P.
    Jarząbek, K.
    Kanczuga-Koda, L.
    Wincewicz, A.
    Koda, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/1918747.pdf
    Data publikacji:
    2018
    Wydawca:
    Uniwersytet Medyczny w Białymstoku
    Tematy:
    HBXIP
    survivin
    oncoprotein
    transcription factor
    Opis:
    Nowadays, Hepatitis B X interacting protein (HBXIP) is an object of scientists’ interest worldwide. It is a protein with significant involvement in the development of malignant tumors like breast or ovarian cancer. One of the most important functions of HBXIP is the regulation of cell proliferation, which is related to the progression of a cell cycle. Many studies provide the growing number of evidence that HBXIP plays various important roles, including the regulation of a cell cycle through complexes with survivin, belonging to the inhibitors of apoptosis and interactions with transcriptional factors like STAT4, SP1, TFIID or E2F1. It also has the influence on the promotion of tumor angiogenesis thanks to the association with VEGF and FGF8. Another important role of HBXIP is a reprogramming of glucose metabolism to conditions favorable to growing cancerous cells due to regulating the activation of SCO2 and PDHA1. Furthermore, it impacts on the complement-dependent cytotoxicity, also, HBXIP affects on lipid metabolism through disturbing of metabolic pathways of FAS. According to recent studies, HBXIP can be used as a prognostic biomarker in many tumors, including cervical cancer, ovarian cancer, and esophageal squamous cell carcinoma thanks to the high expression of this protein noted exclusively in these tumor tissues. What is even more interesting, it significantly correlates with clinical attributes like metastasis to lymph nodes or grading and in some cases can potentially be used as the indicator of prognosis of treatment effectiveness. The paper is review through main functions of HBXIP and its possible applications.
    Źródło:
    Progress in Health Sciences; 2018, 8(2); 215-222
    2083-1617
    Pojawia się w:
    Progress in Health Sciences
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-6 z 6

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies